What did @katiepeptalks actually say?
Katie's claim is straightforward: most peptides are injected subcutaneously, meaning into the fatty tissue just beneath the skin. She lists the stomach, upper thigh, back of the arm, and glute as common injection sites. She also says she rotates sites to avoid irritation and scar tissue buildup, especially during daily injections.
She's not making dramatic therapeutic claims here. This is practical injection technique advice, and she frames it appropriately as "what I've learned." That kind of epistemic humility is actually rare in peptide content on TikTok, so it's worth noting upfront. The question is whether the substance of what she said holds up.
Does the science back this up?
Yes, mostly. Subcutaneous injection is the standard delivery route for most peptides used in clinical and research contexts, and the anatomical sites she names are the ones consistently used in both clinical trials and injection training literature. Site rotation is also a well-supported practice.
The reason peptides are administered subcutaneously rather than orally is their susceptibility to proteolytic degradation in the gastrointestinal tract. Peptide bonds are cleaved by enzymes like pepsin and trypsin before the molecule can reach systemic circulation intact. A 2019 review by Fosgerau and Hoffmann in Drug Discovery Today outlines this bioavailability problem in detail, noting oral bioavailability for most therapeutic peptides is below 1-2% without specialized delivery systems. SubQ injection bypasses this entirely, allowing absorption through the subcutaneous capillary and lymphatic network.
Site rotation has solid support from the diabetes literature, where daily subcutaneous insulin injections are the norm. A 2016 study by Johansson et al. in Diabetes Care found that lipohypertrophy, a form of subcutaneous tissue damage, occurred in a significant proportion of insulin users who did not rotate sites, and this directly affected insulin absorption consistency. The same tissue mechanics apply to peptide injections.
What did they get wrong (or right)?
She got the core facts right. The claim that "most peptides" are injected subcutaneously is accurate for the category of peptides she's discussing, which include GHK-Cu, BPC-157, and similar short-chain bioactive peptides. Some peptides are administered intramuscularly or intranasally, so "most" is doing some work here, but it's not wrong for the peptide therapy space she's describing.
One thing she glosses over: not all peptides behave the same subcutaneously. GHK-Cu, for example, is also used topically in cosmetic formulations, and there's ongoing debate about whether subcutaneous administration meaningfully outperforms topical application for certain skin-related outcomes. A 2015 review by Pickart et al. in Journal of Aging Science covered GHK-Cu's wound-healing properties but noted that route of administration matters for tissue targeting. That nuance is absent from the video, though to be fair, she never claimed to cover it.
The scar tissue comment is accurate. Repeated injections in the same spot can cause subcutaneous fibrosis over time. This isn't alarmist. It's documented clinical reality, and the recommendation to rotate is appropriate and responsible.
What should you actually know?
A few things Katie's video doesn't cover that are worth knowing if you're researching this topic. First, subcutaneous injection technique matters more than most people realize. Injecting too shallowly deposits the compound intradermally, which causes more irritation and inconsistent absorption. Injecting too deep risks intramuscular delivery, which has different absorption kinetics.
Second, the regulatory status of injectable peptides sold outside of licensed pharmacy channels is a real issue. Many peptides circulating in the wellness and biohacking space are sold as "research chemicals" and have not been evaluated for sterility, endotoxin levels, or accurate dosing by any regulatory body. A 2023 analysis published in JAMA Internal Medicine by Cohen et al. found significant labeling inaccuracies and contamination risks in unregulated peptide products. This doesn't make the injection technique advice wrong, but it does mean the vector carrying the compound matters enormously.
Third, GHK-Cu specifically is interesting because it does have a legitimate body of research, but most of that research is either in vitro or animal-based. Human clinical trial data is thin. That doesn't make it useless, but it means claims about its effects should be held loosely.
- Always use a new, sterile needle for each injection if self-administering under medical supervision.
- Injection site reactions, including redness and swelling, can indicate poor technique, contamination, or an immune response to the compound itself.
- If you're pursuing peptide therapy, work with a licensed provider who can source from a regulated compounding pharmacy with USP 797 compliance.